AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$XENE

Kelly Thomas Patrick purchased $560K of XENE

Kelly Thomas Patrick (Chief Financial Officer) purchased 15,000 shares of Xenon Pharmaceuticals Inc. (XENE) at $37.32 ($0.56M total) on 2026-09-30.

Original reporting
SEC EDGAR · Kelly Thomas Patrick
Published Oct 1, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$XENE
Bullish
medium confidence
Mentioned
$XENE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XENEBullishLow
01

Why it matters

The CFO's purchase adds a modest bullish cue but is unlikely to move the stock significantly.

02

Market read

Small insider buy provides a mild positive signal for XENE traders.

03

What to watch

The CFO's purchase may be offset by broader sector weakness or upcoming clinical trial risks.

Relevance 6/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$XENEBullishMedium confidence
Context

CFO Kelly Thomas Patrick bought 15,000 shares of Xenon Pharmaceuticals for $559,740 on 2026-09-30.

Expected impact

likely modest upward pressure as market prices in CFO confidence

Evidence & confidence

The transaction size is small relative to market cap, but insider buying is a bullish signal.

Market effects

Sector

Biotech sector may see slight positive sentiment from insider buying.

Regional

U.S. market impact minimal.

Global

Limited to investors tracking Xenon Pharmaceuticals.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing, not a strong endorsement.

Key entities

  • person
    Kelly Thomas Patrick

    Chief Financial Officer of Xenon Pharmaceuticals

  • company
    Xenon Pharmaceuticals Inc.

    Biotech firm developing oncology therapies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XENE insider trading history →

Related articles

$XENEMedAI 8/10

Xenon (XENE) Q3 2026 Earnings Call Transcript

Xenon Pharmaceuticals (XENE) reported Q3 2026 progress, including FDA NDA submission for AZK, its epilepsy drug candidate. AZK showed significant efficacy in reducing seizure frequency and a strong safety profile. The company also announced plans for a Phase IIIb/IV study (X-FIRST) and progress in its psychiatry and pain programs, including XEN1701 and XEN1120. Enrollment in the Phase III X-NOVA2 study for MDD was completed, with data expected in December 2026.

finance.yahoo.com
$XENEMed

Xenon Pharmaceuticals Inc (XENE) (Q3 2026) Earnings Call Highlights

Xenon Pharmaceuticals (XENE) reported $1.2B in cash reserves, funding operations into 2029. CEO Ian Mortimer discussed azetukalner's (AZK) potential in epilepsy and psychiatry, noting X-NOVA2 data due in December 2026. XEN1701's development was addressed, with the company confident in its design and safety profile. X-FIRST study plans were outlined, targeting earlier-line patients and general neurologists. Dose selection and FDA feedback were also discussed.

finance.yahoo.com
$XENEMedAI 8/10

Xenon Pharmaceuticals Q3 Earnings Call Highlights

Xenon Pharmaceuticals reported Q3 updates, highlighting its epilepsy drug AZK's success in clinical trials, with a 42.7% median reduction in seizures. The company plans to start a phase IIIb/IV study in 2027 and is preparing for commercial launch. Xenon also expects to initiate phase II studies for pain candidates XEN1701 and XEN1120 in early 2027. With $1.2 billion in cash, the company's runway extends into 2029.

finance.yahoo.com
$XENEMed

Why is Xenon Pharmaceuticals stock sliding today?

Xenon Pharmaceuticals (XENE) stock fell 2.4% in after-hours trading to $39.50 after reporting Q3 2026 results. The company posted a net loss of $110.4M, beating estimates but widening from the prior year. Revenue missed forecasts. R&D expenses rose due to late-stage programs. The stock was pressured by a voluntary pause in depression trials. The company submitted a New Drug Application for azetukalner and reported a $1.15B cash position.

investing.com
$XENEMed

Xenon Reports Q3 2026 Financial Results and Provides Business Update

Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Xenon Reports Q3 2026 Financial Results and Provides Business Update • New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 • Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3

SEC EDGAR 8-K